Drug Trial Radar · NCT00435279
A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia
Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
678
Actual
Start
Jun 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the antidepressant effect of adjunctive treatment with Eszopiclone in subjects receiving venlafaxine for the treatment of Major Depressive Disorder (MDD).
Conditions
- Major Depressive Disorder
- Insomnia
Interventions
EszopicloneDrug
Eszopiclone 3 mg
PlaceboDrug
Placebo
VenlafaxineDrug
Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint is the change from baseline in HAM-D-17 total score at Week 8.Time frame: Week 8
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Split, Croatia
Site not named
Zagreb, Croatia
Site not named
Zagreb, Croatia
Site not named
Arcachon, France
Site not named
Caen, France
Site not named
Élancourt, France
Site not named
Le Pecq, France
Site not named
Rennes, France
Site not named
Savigny-sur-Orge, France
Site not named
Strasbourg, France
Site not named
Toulouse, France
Site not named
Toulouse, France
Site not named
Toulouse, France
Site not named
Verasailles, France
Site not named
Balassagyarmat, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Cegléd, Hungary
Site not named
Nyíregyháza, Hungary
Site not named
Bełchatów, Poland
Site not named
Bydgoszcz, Poland
Site not named
Krakow, Poland
Site not named
Lodz, Poland
Site not named
Lublin, Poland
Site not named
Torun, Poland
Site not named
Tuszyn, Poland
Site not named
Bucharest, Romania
Site not named
Lasi, Romania
Site not named
Oradea, Romania
Site not named
Arkhangelsk, Russia
Site not named
Belchatow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Site not named
Saint Petersburg, Russia
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.